Intervention
BIA 9-1067
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 25 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
25 shownEfficacy and Safety of Opicapone in Clinical PracticeNCT02847442 · 2016-11-23
COMPLETEDEffect of Opicapone at Steady State on Warfarin PharmacokineticsNCT02305030 · 2014-03-01
COMPLETEDEffect of Paracetamol on Opicapone Pharmacokinetics in Healthy VolunteersNCT02305017 · 2014-03-01
COMPLETEDThe Effect of BIA 9-1067 at Steady-state on the Levodopa PharmacokineticsNCT02170376 · 2011-09-01
COMPLETEDPharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian SubjectsNCT01520987 · 2011-05-01
COMPLETEDEfficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" PhenomenonNCT01568073 · 2011-03-01
COMPLETEDEfficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.NCT01227655 · 2011-03-01
COMPLETEDEffect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and WomenNCT01532115 · 2010-05-01
COMPLETEDPharmacokinetics of BIA 9-1067 in Subjects With Hepatic ImpairmentNCT02101190 · 2010-03-01
COMPLETEDMulticentre Study in Four Parallel Groups of Parkinson's Disease (PD) PatientsNCT01568047 · 2010-02-01
COMPLETEDEffect of Rasagiline on BIA 9-1067 PharmacokineticsNCT01532141 · 2009-11-01
COMPLETEDEffect of BIA 9-1067 on Rasagiline PharmacokineticsNCT01532128 · 2009-11-01
COMPLETEDEffect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of WarfarinNCT02169440 · 2009-06-01
COMPLETEDEffect of BIA 9-1067 on the Pharmacokinetics of RepaglinideNCT01536366 · 2009-06-01
COMPLETEDAbsorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and MetabolitesNCT01515891 · 2009-05-01
COMPLETEDA Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067NCT01568034 · 2009-04-01
COMPLETEDEffect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/BenserazideNCT01533116 · 2009-03-01
COMPLETEDPharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/CarbidopaNCT01533077 · 2009-03-01
COMPLETEDPharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/BenserazideNCT02169466 · 2009-01-01
COMPLETEDPharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects and in Healthy Male Young SubjectsNCT02092168 · 2008-10-01
COMPLETEDPharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/CarbidopaNCT02169453 · 2008-10-01
COMPLETEDPharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/BenserazideNCT02169895 · 2008-09-01
COMPLETEDPharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/CarbidopaNCT02169479 · 2008-09-01
COMPLETEDTolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067NCT02071810 · 2008-04-01
COMPLETEDA Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male SubjectsNCT01520727 · 2007-10-01
COMPLETEDCommon conditions
Leading sponsors
Trial status mix
COMPLETED25
Phase mix
PHASE120
PHASE22
PHASE32
PHASE41
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.